About Second Sight Medical (NASDAQ:EYES)
Second Sight Medical Products, Inc. develops, manufactures, and markets prosthetic devices to restore functional vision to blind individuals in the United States, Italy, Germany, France, Canada, and Singapore. The company's product is the Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYES
CUSIPN/A
Phone818-833-5000
Debt
Debt-to-Equity RatioN/A
Current Ratio1.99%
Quick Ratio1.58%
Price-To-Earnings
Trailing P/E Ratio-2.83
Forward P/E Ratio-2.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.96 million
Price / Sales12.56
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book11.93
Profitability
EPS (Most Recent Fiscal Year)($0.59)
Net Income$-28,510,000.00
Net Margins-358.06%
Return on Equity-197.61%
Return on Assets-143.82%
Miscellaneous
Employees112
Outstanding Shares59,880,000
Second Sight Medical (NASDAQ:EYES) Frequently Asked Questions
What is Second Sight Medical's stock symbol?
Second Sight Medical trades on the NASDAQ under the ticker symbol "EYES."
How were Second Sight Medical's earnings last quarter?
Second Sight Medical (NASDAQ:EYES) posted its quarterly earnings results on Wednesday, March, 7th. The medical device company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01. The medical device company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $1.98 million. Second Sight Medical had a negative return on equity of 197.61% and a negative net margin of 358.06%. The business's revenue was up 333.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.24) EPS. View Second Sight Medical's Earnings History.
When is Second Sight Medical's next earnings date?
What price target have analysts set for EYES?
1 equities research analysts have issued 12 month target prices for Second Sight Medical's shares. Their forecasts range from $5.00 to $5.00. On average, they expect Second Sight Medical's stock price to reach $5.00 in the next year. View Analyst Ratings for Second Sight Medical.
What are Wall Street analysts saying about Second Sight Medical stock?
Here are some recent quotes from research analysts about Second Sight Medical stock:
- 1. According to Zacks Investment Research, "Second Sight Medical Products, Inc. is a medical device company. It develops, manufactures, and markets implantable prosthetic devices to restore some functional vision to blind patients. The Company provides Argus II system, an implantable neurostimulation device for the treatment of outer retinal degenerations, such as retinitis pigmentosa. Second Sight Medical Products, Inc. is headquartered in Sylmar, California. " (1/8/2018)
- 2. HC Wainwright analysts commented, "We expect that the second pilot study could start in late 3Q17 or early 4Q17 and report top-line data by the end of 2017. Investors may recall that this second pilot study is double-masked and slated to enroll up to 45 subjects. The primary endpoint is the percentage of subjects achieving complete wound healing (based on staining) on day 3. Assuming that the second pilot study shows OBG’s ability to heal corneal defects faster than the standard of care, as was seen in the first pilot study, we believe that EyeGate may only need to conduct a single pivotal study in 2018 before filing for regulatory approval. We note that the FDA has permitted EyeGate to pursue U.S. regulatory clearance for OBG through the de novo 510(k) pathway." (8/8/2017)
Who are some of Second Sight Medical's key competitors?
Some companies that are related to Second Sight Medical include Helius Medical Technologies (HSDT), Zynex (ZYXI), Biolife Solutions (BLFS), Viveve Medical (VIVE), Edap Tms (EDAP), IRIDEX (IRIX), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO), Digirad (DRAD), Aradigm (ARDM), Dynatronics (DYNT), EnteroMedics (RSLS), CHF Solutions (CHFS), FC Global Realty (FCRE), Trimedyne (TMED), IMRIS (IMRSQ) and Echo Therapeutics (ECTE).
Who are Second Sight Medical's key executives?
Second Sight Medical's management team includes the folowing people:
- Mr. Jonathan Will McGuire, Chief Exec. Officer, Pres and Director (Age 55)
- Mr. Thomas B. Miller, CFO & Corp. Sec. (Age 62)
- Mr. Edward David Randolph, VP of Manufacturing (Age 60)
- Mr. Stephen D. Okland Jr., Commercial VP for US & Canada (Age 54)
When did Second Sight Medical IPO?
(EYES) raised $32 million in an initial public offering (IPO) on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.
Has Second Sight Medical been receiving favorable news coverage?
News coverage about EYES stock has been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Second Sight Medical earned a daily sentiment score of 0.24 on Accern's scale. They also assigned media stories about the medical device company an impact score of 45.65 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Second Sight Medical?
Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Second Sight Medical's stock price today?
One share of EYES stock can currently be purchased for approximately $1.67.
How big of a company is Second Sight Medical?
Second Sight Medical has a market capitalization of $104.18 million and generates $7.96 million in revenue each year. The medical device company earns $-28,510,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Second Sight Medical employs 112 workers across the globe.
How can I contact Second Sight Medical?
Second Sight Medical's mailing address is 12744 SAN FERNANDO ROAD BLDG. 3, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]
MarketBeat Community Rating for Second Sight Medical (EYES)
MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical and other stocks. Vote "Outperform" if you believe EYES will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYES will underperform the S&P 500 over the long term. You may vote once every thirty days.
Second Sight Medical (NASDAQ:EYES) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Second Sight Medical in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 199.40%. The high price target for EYES is $5.00 and the low price target for EYES is $5.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.00 | $5.00 | $5.00 | $5.00 |
| Price Target Upside: | 199.40% upside | 116.45% upside | 339.44% upside | 342.48% upside |
Second Sight Medical (NASDAQ:EYES) Consensus Price Target History
Second Sight Medical (NASDAQ:EYES) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 2/5/2018 | HC Wainwright | Set Price Target | Buy | $5.00 | High |  |
| 7/26/2016 | Rodman & Renshaw | Reiterated Rating | Buy | $16.00 | N/A | |
(Data available from 4/19/2016 forward)
Second Sight Medical (NASDAQ:EYES) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Second Sight Medical (NASDAQ EYES) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 34.70%
Institutional Ownership Percentage: 12.79%
Second Sight Medical (NASDAQ EYES) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/20/2017 | Gregg Williams | Director | Buy | 17,020 | $1.18 | $20,083.60 | | |
| 11/17/2017 | Gregg Williams | Director | Buy | 5,420 | $1.17 | $6,341.40 | | |
| 4/7/2017 | Gregg Williams | Director | Buy | 4,000,000 | $1.00 | $4,000,000.00 | | |
| 12/1/2016 | Robert J Greenberg | Chairman | Sell | 1,950 | $1.96 | $3,822.00 | 172,911 | |
| 6/3/2016 | Edward David Randolph | VP | Sell | 5,104 | $4.01 | $20,467.04 | | |
| 6/2/2016 | Robert J Greenberg | Chairman | Sell | 8,571 | $4.10 | $35,141.10 | 172,911 | |
| 4/18/2016 | Robert J Greenberg | Chairman | Sell | 8,223 | $5.27 | $43,335.21 | 181,134 | |
| 12/7/2015 | Robert J. Greenberg | Chairman | Sell | 17,969 | $5.30 | $95,235.70 | 172,911 | |
| 12/4/2015 | Anne-Marie Juliette Ripley | VP | Sell | 2,500 | $5.50 | $13,750.00 | | |
| 6/4/2015 | Anne-Marie Juliette Ripley | VP | Sell | 4,371 | $15.00 | $65,565.00 | | |
| 6/3/2015 | Robert J Greenberg | CEO | Sell | 150,000 | $14.04 | $2,106,000.00 | | |
| 5/27/2015 | Anne-Marie Juliette Ripley | VP | Sell | 45,629 | $13.04 | $595,002.16 | | |
| 3/23/2015 | Robert J Greenberg | CEO | Sell | 100,000 | $13.28 | $1,328,000.00 | | |
| 11/19/2014 | Gregg Williams | Director | Buy | 111,111 | $9.00 | $999,999.00 | | |
(Data available from 1/1/2013 forward)
Second Sight Medical (NASDAQ EYES) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Second Sight Medical (EYES) vs. Edap Tms (EDAP) Head-To-Head Analysis
www.americanbankingnews.com - April 17 at 5:37 PM |
| Second Sight Medical (EYES) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 12 at 9:00 PM |
 | Second Sight Medical (EYES) Announces Dr. Robert Greenberg's Resignation from Board of Directors
www.streetinsider.com - April 10 at 10:53 AM |
 | Second Sight Announces Dr. Robert Greenberg’s Resignation from Board of Directors and as an Officer of the Company
finance.yahoo.com - April 10 at 10:53 AM |
| Second Sight Medical (EYES) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - April 6 at 9:50 PM |
| Second Sight Medical (EYES) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 31 at 4:56 PM |
| HC Wainwright Reiterates "$5.00" Price Target for Second Sight Medical Products (EYES)
www.americanbankingnews.com - March 25 at 11:41 AM |
| Second Sight Medical (EYES) Names John T. Blake as Chief Financial Officer - StreetInsider.com
www.streetinsider.com - March 22 at 3:51 PM |
| Second Sight Medical (EYES) Names Gregg Williams to Board - StreetInsider.com
www.streetinsider.com - March 16 at 3:39 PM |
| Second Sight Medical (EYES) Names Gregg Williams to Board
www.streetinsider.com - March 16 at 11:34 AM |
| Second Sight Appoints Gregg Williams as Chairman of the Board of Directors
finance.yahoo.com - March 16 at 11:34 AM |
| Second Sight Medical Products, Inc. to Present at the B. Riley & Co. China Healthcare Investment Partnering Symposium
finance.yahoo.com - March 9 at 10:41 AM |
 | Second Sight Medical Products' (EYES) CEO Will McGuire on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 8 at 3:40 PM |
| Second Sight Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 10:45 AM |
| Second Sight Medical Products (EYES) Announces Earnings Results
www.americanbankingnews.com - March 7 at 9:14 PM |
| Second Sight Medical Products, Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 3:38 PM |
| Second Sight Medical (EYES) Reports Expansion of Medicare ... - StreetInsider.com
www.streetinsider.com - March 6 at 3:35 PM |
| Second Sight Medical (EYES) Reports Expansion of Medicare Coverage for Argus II Retinal Prosthesis
www.streetinsider.com - March 6 at 10:52 AM |
| Second Sight Announces Latest Expansion of Medicare Coverage for Argus II Retinal Prosthesis System
finance.yahoo.com - March 6 at 10:51 AM |
 | Second Sight Medical Products, Inc. to Present at the Inaugural LD ... - Business Wire (press release)
www.businesswire.com - March 5 at 3:46 PM |
| Second Sight Medical Products, Inc. to Present at the Inaugural LD Micro Virtual Investor Conference on March 7, 2018
finance.yahoo.com - March 5 at 11:14 AM |
| Second Sight to Discuss Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018 Conference Call
finance.yahoo.com - February 28 at 10:52 AM |
| Second Sight Medical Products (EYES) to Release Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:58 AM |
| Second Sight Medical (EYES) Gains Following Entry into Singapore - StreetInsider.com
www.streetinsider.com - February 17 at 3:37 PM |
| Second Sight Announces Market Entry into Singapore with First Implant of Argus II Retinal Prosthesis System
finance.yahoo.com - February 16 at 9:59 AM |
| Second Sight Medical Products (EYES) vs. Amedica (AMDA) Head-To-Head Review
www.americanbankingnews.com - February 15 at 12:46 PM |
| First Look At Second Sight - Seeking Alpha
seekingalpha.com - February 8 at 5:16 AM |
| Second Sight Medical, Investors Open Their Eyes Making These Shares Soar, Recent Developments
finance.yahoo.com - February 8 at 5:16 AM |
 | Second Sight (EYES) Catches Eye: Stock Jumps 12.7% - Nasdaq
www.nasdaq.com - February 6 at 3:17 PM |
| Second Sight (EYES) Catches Eye: Stock Jumps 12.7%
finance.yahoo.com - February 6 at 3:17 PM |
| Second Sight Medical Products Inc Execution Is Firing on All Cylinders Following Standout 4Q:17 Implants
finance.yahoo.com - February 6 at 3:17 PM |
 | 33 Biggest Movers From Yesterday - Benzinga
www.benzinga.com - February 6 at 5:25 AM |
| 31 Stocks Moving In Monday's Mid-Day Session | Benzinga - Benzinga
www.benzinga.com - February 6 at 5:25 AM |
| Pre-Open Movers 02/05: (CAPR) (EYES) (BG) Higher; (WFC) (DKS) (QCOM) Lower (more...) - StreetInsider.com
www.streetinsider.com - February 5 at 3:17 PM |
| Mid-Afternoon Market Update: Dow Tumbles Over 400 Points; Crude Oil Down 2% - Benzinga
www.benzinga.com - February 5 at 3:17 PM |
| Second Sight Medical (EYES) Provides Update on Key Performance Metrics - StreetInsider.com
www.streetinsider.com - February 5 at 3:17 PM |
| Second Sight Announces Record Number of Argus II Retinal Prosthesis Systems Implants and Completes First-in-Human Orion Cortical Implant
finance.yahoo.com - February 5 at 3:17 PM |
| Second Sight Medical Products Inc (EYES) Given $5.00 Consensus Target Price by Analysts
www.americanbankingnews.com - February 3 at 3:22 PM |
 | Pre-Market Technical Scan on Medical Equipment Equities -- Senseonics, Aethlon Medical, CHF Solutions, and ... - PR Newswire (press release)
www.prnewswire.com - January 22 at 7:45 AM |
| Zacks: Analysts Set $5.00 Price Target for Second Sight Medical Products Inc (EYES)
www.americanbankingnews.com - January 22 at 1:20 AM |
| Second Sight Medical Products (EYES) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - January 8 at 11:30 PM |
| January Growth Opportunities – Athenex And More
finance.yahoo.com - December 31 at 5:05 PM |
| Comparing Second Sight Medical Products (EYES) & Its Rivals
www.americanbankingnews.com - December 22 at 9:20 PM |
| Second Sight Medical Products (EYES) & Its Competitors Head-To-Head Review
www.americanbankingnews.com - December 20 at 9:32 AM |
| Second Sight Medical Products (EYES) vs. Its Rivals Head-To-Head Comparison
www.americanbankingnews.com - December 19 at 3:26 PM |
| Critical Review: Second Sight Medical Products (EYES) versus The Competition
www.americanbankingnews.com - December 19 at 9:32 AM |
| Zacks: Second Sight Medical Products, Inc. (EYES) Given $5.00 Average Target Price by Brokerages
www.americanbankingnews.com - December 18 at 3:28 PM |
| Second Sight Medical Products (EYES) versus Its Competitors Critical Analysis
www.americanbankingnews.com - December 17 at 1:28 AM |
| Second Sight Medical Products (EYES) & Its Rivals Financial Review
www.americanbankingnews.com - December 15 at 9:14 AM |
| Second Sight Medical Products (EYES) vs. Its Rivals Head to Head Comparison
www.americanbankingnews.com - December 12 at 7:34 PM |
Second Sight Medical (NASDAQ:EYES) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Second Sight Medical (NASDAQ:EYES) Income Statement, Balance Sheet and Cash Flow Statement
Second Sight Medical (NASDAQ EYES) Stock Chart for Thursday, April, 19, 2018
Loading chart…
